Evidence map›Paper›PMID 33774082›Full record

ArticleKidney international2021

Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection.

Candice L Clarke, Maria Prendecki, Amrita Dhutia, Jaslyn Gan, Claire Edwards, Virginia Prout, Liz Lightstone, Eleanor Parker, Federica Marchesin, Megan Griffith and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Candice L ClarkeCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK; Imperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK. Electronic address: candice.clarke@imperial.ac.uk.
Maria PrendeckiCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK; Imperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Amrita DhutiaImperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Jaslyn GanImperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Claire EdwardsImperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Virginia ProutImperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Liz LightstoneCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK; Imperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Eleanor ParkerImmunology of Infection Group, Department of Infectious Diseases, Imperial College London, London, UK.
Federica MarchesinImmunology of Infection Group, Department of Infectious Diseases, Imperial College London, London, UK.
Megan GriffithImperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Rawya CharifImperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Graham PickardDepartment of Infection and Immunity, North West London Pathology NHS Trust, London, UK.
Alison CoxDepartment of Infection and Immunity, North West London Pathology NHS Trust, London, UK.
Myra McClureImmunology of Infection Group, Department of Infectious Diseases, Imperial College London, London, UK.
Richard TedderImmunology of Infection Group, Department of Infectious Diseases, Imperial College London, London, UK.
Paul RandellDepartment of Infection and Immunity, North West London Pathology NHS Trust, London, UK.
Louise GreatheadDepartment of Infection and Immunity, North West London Pathology NHS Trust, London, UK.
Mary GuckianDepartment of Infection and Immunity, North West London Pathology NHS Trust, London, UK.
Stephen P McAdooCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK; Imperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Peter KelleherImmunology of Infection Group, Department of Infectious Diseases, Imperial College London, London, UK; Department of Infection and Immunity, North West London Pathology NHS Trust, London, UK.
Michelle WillicombeCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK; Imperial College Renal and Transplant Centre, Division of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.

Funding

Medical Research Council MC_PC_19078
6 · The paper itself

Abstract

Patients with end stage kidney disease receiving in-center hemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. Following infection, patients receiving ICHD frequently develop circulating antibodies to SARS-CoV-2, even with asymptomatic infection. Here, we investigated the durability and functionality of the immune responses to SARS-CoV-2 infection in patients receiving ICHD. Three hundred and fifty-six such patients were longitudinally screened for SARS-CoV-2 antibodies and underwent routine PCR-testing for symptomatic and asymptomatic infection. Patients were regularly screened for nucleocapsid protein (anti-NP) and receptor binding domain (anti-RBD) antibodies, and those who became seronegative at six months were screened for SARS-CoV-2 specific T-cell responses. One hundred and twenty-nine (36.2%) patients had detectable antibody to anti-NP at time zero, of whom 127 also had detectable anti-RBD. Significantly, at six months, 71/111 (64.0%) and 99/116 (85.3%) remained anti-NP and anti-RBD seropositive, respectively. For patients who retained antibody, both anti-NP and anti-RBD levels were reduced significantly after six months. Eleven patients who were anti-NP seropositive at time zero, had no detectable antibody at six months; of whom eight were found to have SARS-CoV-2 antigen specific T cell responses. Independent of antibody status at six months, patients with baseline positive SARS-CoV-2 serology were significantly less likely to have PCR confirmed infection over the following six months. Thus, patients receiving ICHD mount durable immune responses six months post SARS-CoV-2 infection, with fewer than 3% of patients showing no evidence of humoral or cellular immunity.

Indexed as

Antibodies, ViralCOVID-19COVID-19 TestingFemaleHumansImmunityKidney Failure, ChronicMalePandemicsPolymerase Chain ReactionReinfectionRenal DialysisSARS-CoV-2Serologic TestsAntibodies, ViralCOVID-19hemodialysisSARS-CoV-2serology

Identifiers

PMID33774082
PMCPMC7992297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.